Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on October 7, 2011, regarding events occurring on October 4, 2011. The filing addresses a corporate governance matter involving a stockholder vote on a proposed reverse stock split.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action and does not contain financial performance data.
Material Changes
The primary material change is the receipt of written consent from stockholders holding a majority of outstanding common stock to amend the Company's Amended and Restated Certificate of Incorporation. This amendment permits the Board of Directors to effect a reverse stock split of common stock at any time prior to September 30, 2012.
- Split Ratio: Not less than one-for-two and not more than one-for-ten.
- Authorized Shares: The number of authorized shares will be reduced by the same ratio as the reverse stock split.
- Voting Results:
- Consented: 37,720,650 shares (50.72% of shares entitled to vote).
- Withheld Consent: 1,672,555 shares (2.25%).
- Abstained: 14,101 shares (0.02%).
- Total Shares Entitled to Vote: 74,368,568.
Guidance, Outlook, and Risks
Management commentary indicates that while stockholder approval has been secured, the Board of Directors retains the sole discretion to elect not to proceed with the reverse stock split. The Board may decide not to file the Certificate of Amendment if it determines that proceeding is no longer in the best interest of the Company or its stockholders. The consent solicitation has expired by its terms following the receipt of requisite consents.
Investor Verification Checklist
- Verify the exact reverse stock split ratio once determined by the Board of Directors.
- Confirm the filing date of the Certificate of Amendment with the state of Delaware.
- Monitor for any subsequent announcement from the Board regarding the decision to proceed or abandon the split.
- Check the updated number of authorized and outstanding shares after the potential implementation of the split.